CellCarta acquires Biogazelle to strengthen its genomic capabilities
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Subscribe To Our Newsletter & Stay Updated